Search Results - "Mantha, Simon"
-
1
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
Published in Journal of thrombosis and thrombolysis (01-02-2015)“…Four target-specific oral anticoagulants (TSOA’s) have been compared to a vitamin K antagonist for the treatment of acute venous thromboembolism (VTE):…”
Get full text
Journal Article -
2
Whatʼs new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?
Published in Current opinion in hematology (01-03-2016)“…PURPOSE OF REVIEWAcute promyelocytic leukemia (APL) is associated with a complex coagulopathy. In spite of substantial recent improvements in treatment…”
Get full text
Journal Article -
3
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
Published in Journal of thrombosis and thrombolysis (01-02-2017)“…Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was…”
Get full text
Journal Article -
4
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
Published in Blood (30-03-2017)“…Acute promyelocytic leukemia (APL) is commonly complicated by a complex coagulopathy. Uncertainty remains as to which markers of bleeding risk are independent…”
Get full text
Journal Article -
5
Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot
Published in Bleeding, Thrombosis and Vascular Biology (01-01-2024)“…The goal of machine learning (ML) is to create informative signals and useful tasks by leveraging large datasets to derive computational algorithms. ML has the…”
Get full text
Journal Article -
6
Predictive factors of fatal bleeding in acute promyelocytic leukemia
Published in Thrombosis research (01-04-2018)“…Acute promyelocytic leukemia (APL) is associated with a profound coagulopathy. Based on retrospective assessments, several potential risk factors for…”
Get full text
Journal Article -
7
Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
Published in Gynecologic oncology reports (01-06-2024)“…•Chemotherapy-induced thrombocytopenia is common among patients with gynecologic or breast cancer during treatment.•64 % of patients with gynecologic or breast…”
Get full text
Journal Article -
8
Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer
Published in The American journal of cardiology (27-04-2017)“…Abstract Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with non-valvular atrial fibrillation…”
Get full text
Journal Article -
9
Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
Published in Research and practice in thrombosis and haemostasis (01-07-2019)“…Low‐molecular‐weight heparin has been the preferred treatment of cancer‐associated thrombosis (CAT); however, emerging data support the use of direct oral…”
Get full text
Journal Article -
10
Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance
Published in American journal of obstetrics and gynecology (01-08-2015)“…Objective Ovarian vein thrombosis is associated with pregnancy and pelvic surgery. Postpartum ovarian vein thrombosis is associated with infection and a high…”
Get full text
Journal Article -
11
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
Published in Research and practice in thrombosis and haemostasis (01-03-2022)“…Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity…”
Get full text
Journal Article -
12
Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic
Published in Journal of thrombosis and thrombolysis (01-10-2011)“…Oral anticoagulation with warfarin is widely used to treat venous and arterial thromboembolic disease (Ansell et al. Chest 133(6 suppl):160S–198S, 2008 ). Its…”
Get full text
Journal Article -
13
Cancer genetic alterations and risk of venous thromboembolism
Published in Thrombosis research (01-05-2022)“…Cancer has long been known to incur an increased risk of venous thromboembolism (VTE). Multiple risk factors for cancer-associated thrombosis (CAT) have been…”
Get full text
Journal Article -
14
Dynamic Modelling for Cancer-Associated Venous Thromboembolism
Published in Blood (02-11-2023)“…Background: Cancer-associated venous thromboembolism (VTE) is an important source of morbidity and mortality. Current risk prediction models for thrombosis are…”
Get full text
Journal Article -
15
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
Published in Thrombosis and haemostasis (01-09-2012)“…New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two…”
Get more information
Journal Article -
16
Prediction of COVID-19 Mortality in Patients with Cancer
Published in Blood (05-11-2020)“…Background: Coronavirus disease 2019 (COVID-19) is associated with an increased mortality rate in patients with cancer. Machine learning approaches have been…”
Get full text
Journal Article -
17
Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses
Published in Journal of thrombosis and thrombolysis (01-08-2013)“…Dabigatran, rivaroxaban, apixaban and edoxaban administered in fixed doses and without routine laboratory monitoring have been compared to warfarin for the…”
Get full text
Journal Article -
18
P15 Use of romiplostim in chemotherapy-induced thrombocytopenia in gynecologic and breast cancers
Published in Gynecologic oncology (01-07-2023)Get full text
Journal Article -
19
Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease
Published in Blood (15-11-2013)“…Three target-specific oral anticoagulants (TSOA's) have been recently compared to standard therapy with a vitamin K antagonist (VKA) for the treatment of acute…”
Get full text
Journal Article -
20
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study
Published in Journal of thrombosis and thrombolysis (01-05-2017)“…The development of thrombocytopenia in the setting of therapeutic anticoagulation for venous thromboembolic disease (VTE) is common in cancer patients, but…”
Get full text
Journal Article